Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

LY5830966

Small molecule · Inhibitor of Janus kinase 2 (JAK2) · developed by ELI LILLY &

Phase 1 Most advanced trial

LLY Developer

1 Registered trials

What is LY5830966?

LY5830966 is an orally bioavailable type II inhibitor of JAK2 that binds the inactive, DFG-loop-out conformation of the kinase and blocks its ATP-binding site. By preventing JAK2 activation, it reduces STAT3 and STAT5 signaling. It is studied in primary myelofibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AJ1-11095
Drug type: Small molecule
Targets: Janus kinase 2 (JAK2)
Mechanism: Inhibitor of Janus kinase 2 (JAK2)
Pathways: JAK/STAT signaling, STAT3 activation, STAT5 activation
Therapy area: Hematology
Developer: ELI LILLY & (LLY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06343805	Phase 1	Primary Myelofibrosis	Recruiting	LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Primary Myelofibrosis

Other drugs acting on JAK2

Baricitinib FDA approved Fedratinib FDA approved Upadacitinib FDA approved

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Sources

NCI Thesaurus

Updated Oct 11, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind LY5830966

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z